<DOC>
	<DOCNO>NCT01282333</DOCNO>
	<brief_summary>This phase I clinical trial study side effect best dose veliparib gemcitabine hydrochloride give cisplatin treat patient advanced biliary , pancreatic , urothelial , non-small cell lung cancer . Veliparib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , cisplatin gemcitabine hydrochloride , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Veliparib may help cisplatin gemcitabine hydrochloride work well make tumor cell sensitive drug .</brief_summary>
	<brief_title>Veliparib , Cisplatin , Gemcitabine Hydrochloride Treating Patients With Advanced Biliary , Pancreatic , Urothelial , Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum-tolerated dose veliparib ( ABT-888 ) ( day 1-12 21-day schedule ) combination cisplatin ( day 3 ) gemcitabine ( day 3 , 10 ) patient advance , previously untreated carcinoma bile duct , gallbladder pancreas , non-small cell lung cancer , transitional cell carcinoma bladder/urothelial tract . SECONDARY OBJECTIVES : I . Describe dose-limiting toxicity ( DLT ) toxicity associate veliparib combination cisplatin plus gemcitabine assess CTCAE v4.0 . II . Determine recommend phase 2 dose veliparib ( ABT-888 ) ( RP2D ) combination cisplatin plus gemcitabine . III . Document anti-tumor activity veliparib ( ABT-888 ) , cisplatin , gemcitabine assess RECIST 1.1 . IV . Determine plasma pharmacokinetics veliparib ( ABT-888 ) , cisplatin , gemcitabine . V. Determine abundance gemcitabine triphosphate PBMCs follow gemcitabine administration . VI . Measure abundance DNA-platinum adduct tumor tissue follow cisplatin administration . VII . Measure PARP enzymatic activity PBMC tumor tissue follow study treatment . VIII . Perform exploratory correlation abundance BRCA proteins assessed tumor immunohistochemistry clinical response . OUTLINE : This multicenter , dose-escalation study veliparib gemcitabine hydrochloride . Patients stratify accord presence suspect know BRCA mutation ( vs yes ) . Patients receive veliparib orally every 12 hour day 1-12 , gemcitabine hydrochloride IV 30 minute day 3 10 , cisplatin IV 60-120 minute day 3 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients suspect known germline BRCA mutation may continue receive single-agent veliparib continuously absence disease progression unacceptable toxicity . Patients may undergo blood , tumor tissue , hair follicle sample collection periodically pharmacokinetic correlative study . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients must histologically cytologically confirm advanced biliary/pancreatic cancer , urothelial cancer , nonsmall cell lung cancer metastatic unresectable Patients know CNS metastasis exclude clinical trial ECOG performance status ≤ 2 ( Karnofsky ≥ 60 % ) Life expectancy great 12 week Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Total bilirubin within normal institutional limit AST/ALT ≤ 2.5 time institutional upper limit normal Creatinine within normal institutional limit OR creatinine clearance ≥ 60 mL/min QTc interval ECG ≤ 0.48 second Bazett 's calculation ( ≤ CTCAE v.4 grade 2 ) Not pregnant nursing Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation Patients must able swallow pill significant impairment gastrointestinal absorption Patients know suspected germline mutation BRCA1 BRCA2 eligible participate Patients study screen ( primarily pancreatic cancer ) family history suspicious BRCA1 BRCA2 germline mutation assess BRCAPRO computer program quantitate likelihood harbor deleterious BRCA mutation Patients find BRCAPRO probability score ≥ 20 % undergo formal fullsequence BRCA test Patients screen BRCAPRO probability ≥ 20 % decline genetic test eligible participate trial due potential confound safety assessment No uncontrolled intercurrent illness include , limited : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement HIVpositive patient eligible No active seizure history seizure disorder No history allergic reaction attribute compound similar chemical biologic composition veliparib ( ABT888 ) agent use study No peripheral neuropathy great grade1 No prior systemic treatment No prior cytotoxic chemotherapy ( neoadjuvant , adjuvant , metastatic setting ) At least 4 week since major surgery radiation therapy Patients may receive investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>